Gilead said data from NIAID study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating coronavirus patient Gilead Sciences Inc.
said data from a US study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating Covid-19.
The company said in a statement that it is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ study of remdesivir for treating the disease caused by the novel coronavirus.
Gilead shares were halted, but the news appeared to lift the entire US stock market, with futures linked to major US indexes jumping after the company’s statement was issued.